公开(公告)号：US20190194725A1

公开(公告)日：2019-06-27

申请号：US16079450

申请日：2017-02-24

申请人： UCL BUSINESS PLC

发明人： Mahdad NOURSADEGHI ,  Jennifer ROE ,  Adrian MARTINEAU

IPC分类号： C12Q1/689 ,  G01N33/68

CPC分类号： C12Q1/689 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/12 ,  G01N2800/26 ,  G01N2800/56

摘要： The present invention relates to a method of determining the presence or absence of active tuberculosis in a sample, in particular, comprising determining the levels of one or more biomarkers selected from basic leucine zipper transcription factor ATF-like 2 (BATF2), cluster of differentiation 177 (CD177), haptoglobin (HP), immunoglobulin J chain (IGJ) and galectin 10 (CLC), in said sample. Uses of biomarkers of the invention and kits for performing the method of the invention are also described.

公开(公告)号：US20180327843A1

公开(公告)日：2018-11-15

申请号：US15748984

申请日：2016-07-25

申请人： PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

发明人： Alexis Mikes KALERGIS PARRA ,  Susan Marcela BUENO RAMIREZ ,  Jose Pablo BERTRAND NAVARRETE ,  Margarita Kam-Lem LAY REMOLCOI

IPC分类号： C12Q1/6883

CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/005 ,  G01N2333/54 ,  G01N2333/5403 ,  G01N2333/5434 ,  G01N2800/12 ,  G01N2800/54

摘要： The present invention is related to detecting respiratory diseases using molecular markers as prognostic tool of the evolution of respiratory infection cases. Concretely, during the differential diagnostic of respiratory infections caused by the Syncytial Respiratory Virus and human Metapneumovirus, it will be established the expression pattern of the severity markers of IL-3, IL-33 and IL12p40. The expression pattern of the molecular markers can be defined in biological samplers using ELISA assays, flow cytometry or PCR in real time. The confirmation of the etiological agent of the infection in combination to the pattern definition of the molecular markers IL-3, IL-33 and IL12p40 will indicate a prognostic of the disease severity.

公开(公告)号：US20180250275A1

公开(公告)日：2018-09-06

申请号：US15756791

申请日：2016-09-02

申请人： THE HOSPITAL FOR SICK CHILDREN ,  THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

发明人： Johanna M. ROMMENS ,  Lisa STRUG ,  Lei SUN

IPC分类号： A61K31/4245 ,  A61K31/443 ,  A61K31/47 ,  A61P11/00 ,  G01N33/68 ,  C12Q1/6883

CPC分类号： A61K31/4245 ,  A61K31/443 ,  A61K31/47 ,  A61P11/00 ,  C07D215/233 ,  C07D271/06 ,  C07D405/12 ,  C07K14/705 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/48 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2800/12

摘要： Described herein is a genetic modifier of cystic fibrosis (CF), which may serve as a predictor of the efficacy of a CFTR-directed therapy. SNPs rs7512462 or rs2869027 in non-coding regions of SLC26A9 are shown to correlate with CF lung disease severity in patients having CFTR mutations that leave protein at the cell surface, e.g. gating mutations such as G551D. It is also shown that patient response to Ivacaftor correlates with SLC26A9 genotype. Given the biology of SLC26A9, risk alleles of LC26A9 should correlate with reduced SLC26A9. SLC26A9 activity (marked by e.g. genotype or expression level) is therefore a predictor of treatment efficacy for any CFTR-directed therapeutic, such as Ivacaftor or Lumacaftor. Associated methods of selecting and treating patients are described, along with related kits, uses, and drug discovery platforms.

公开(公告)号：US20180180590A1

公开(公告)日：2018-06-28

申请号：US15644793

申请日：2017-07-09

申请人： Richard T. Mahon ,  Aaron A. Hall ,  William A. Cronin

发明人： Aaron A. Hall ,  Richard T. Mahon ,  William A. Cronin

IPC分类号： G01N33/497 ,  G06F19/00 ,  G01N30/72

CPC分类号： G01N33/497 ,  G01N30/72 ,  G01N30/7206 ,  G01N2030/884 ,  G01N2033/4975 ,  G01N2560/00 ,  G01N2800/12 ,  G01N2800/50 ,  G06F19/707

摘要： A set of volatile organic compounds is provided, comprising Benzene, 2,3,4-trimethyl-Pentane, 1,4-dimethyl-, trans-Cyclohexane, 2,2,4-trimethyl-Hexane, 1,7,7-trimethyl-Tricyclo[2.2.1.0(2,6)]heptane, and 4-ethyl-3-Octene for breath analysis. Methods of identifying these VOCs and use thereof in diagnosing, monitoring the onset of pulmonary toxicity are also disclosed.

公开(公告)号：US09945872B2

公开(公告)日：2018-04-17

申请号：US13541462

申请日：2012-07-03

申请人： Jason Flora ,  Barbara K. Zedler ,  Edward Lenn Murrelle ,  Mark Leppert ,  Edwin J. C. G. van den Oord ,  Bradley Todd Webb ,  Timothy York ,  Gaurav S. J. B. Rana ,  Jeffrey S. Edmiston ,  Willie J. McKinney

发明人： Jason Flora ,  Barbara K. Zedler ,  Edward Lenn Murrelle ,  Mark Leppert ,  Edwin J. C. G. van den Oord ,  Bradley Todd Webb ,  Timothy York ,  Gaurav S. J. B. Rana ,  Jeffrey S. Edmiston ,  Willie J. McKinney

IPC分类号： G01N33/68 ,  C40B40/10 ,  C07K17/00 ,  C07H21/00 ,  C40B40/08 ,  C40B20/02 ,  G01N33/574

CPC分类号： G01N33/6893 ,  C07H21/00 ,  C07K17/00 ,  C40B20/02 ,  C40B40/08 ,  C40B40/10 ,  G01N33/57423 ,  G01N33/6848 ,  G01N2800/12 ,  G01N2800/122 ,  G01N2800/60

摘要： Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.

公开(公告)号：US20180011111A1

公开(公告)日：2018-01-11

申请号：US15700226

申请日：2017-09-11

申请人： InfanDx AG

发明人： Matthias Keller ,  Hans-Peter Deigner ,  David Enot ,  Matthias Kohl ,  Ronnaug Solberg ,  Olga Saugstad ,  Therese Koal

IPC分类号： G01N33/68 ,  G06F19/24

CPC分类号： G01N33/6893 ,  G01N2800/12 ,  G16B40/00 ,  Y02A90/26

摘要： A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

公开(公告)号：US09834681B2

公开(公告)日：2017-12-05

申请号：US14613214

申请日：2015-02-03

申请人： The Texas A&M University System ,  The Board of Trustees of the Leland Stanford Junior University

发明人： Jianghong Rao ,  Hexin Xie ,  Yunfeng Cheng ,  Jeffrey D. Cirillo

IPC分类号： C07D501/52 ,  C07D501/62 ,  C09B11/24 ,  C09B57/02 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/34

CPC分类号： C09B11/24 ,  C07D501/52 ,  C07D501/62 ,  C09B57/02 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/34 ,  G01N2333/30 ,  G01N2333/986 ,  G01N2800/12 ,  G01N2800/52

摘要： β-Lactamase substrates and methods for using the substrates to detect β-lactamase and to diagnose tuberculosis.

公开(公告)号：US20170216400A1

公开(公告)日：2017-08-03

申请号：US14910401

申请日：2013-08-09

申请人： BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY

发明人： Xiliang WANG ,  Chengyu JIANG ,  Penghui YANG ,  Xin LIU ,  Yueqiang DUAN ,  Li XING ,  Chengcai LAI

IPC分类号： A61K38/18 ,  G01N33/68

CPC分类号： A61K38/1825 ,  G01N33/6893 ,  G01N2333/50 ,  G01N2800/12

摘要： The present invention provides a novel use of fibroblast growth factor 2 (FGF-2), i.e., a use of FGF-2 in preparation of medicine. The uses of the medicine are the following (a) and/or (b) and/or (c): (a) the prevention and/or treatment of lung injury; (b) the prevention and/or treatment of influenza; (c) the prevention and/or treatment of diseases caused by influenza viruses.

公开(公告)号：US20170108511A1

公开(公告)日：2017-04-20

申请号：US15122304

申请日：2015-03-02

申请人： Mologic Limited

发明人： Gita Parekh ,  Paul Davis

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/6863 ,  G01N2800/12 ,  G01N2800/7095

摘要： Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.

公开(公告)号：US20170089924A1

公开(公告)日：2017-03-30

申请号：US15305879

申请日：2015-03-31

申请人： TOHOKU UNIVERSITY

发明人： Hiroaki SHIMOKAWA ,  Kimio SATOH ,  Nobuhiro KIKUCHI

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/68 ,  G01N2333/47 ,  G01N2800/12

摘要： A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein P protein in a sample derived from a subject.